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Abstract
We compared invasive cervical cancer (ICC) incidence rates in Europe, South Africa, Latin and 
North America among women living with HIV who initiated antiretroviral therapy (ART) between 
1996 and 2014. We analyzed cohort data from the International epidemiology Databases to 
Evaluate AIDS (IeDEA) and the Collaboration of Observational HIV Epidemiological Research in 
Europe (COHERE) in EuroCoord. We used flexible parametric survival models to determine 
regional ICC rates and risk factors for incident ICC. We included 64,231 women from 45 
countries. During 320,141 person-years (pys), 356 incident ICC cases were diagnosed (Europe 
164, South Africa 156, North America 19, Latin America 17). Raw ICC incidence rates per 
100,000 pys were 447 in South Africa (95% confidence interval [CI] 382–523), 136 in Latin 
America (95% CI 85–219), 76 in North America (95% CI 48–119), and 66 in Europe (95% CI 57–
77). Compared with European women ICC rates at 5 years after ART initiation were more than 
double in Latin America (adjusted hazard ratio [aHR] 2.43, 95% CI 1.27–4.68) and 11-times 
higher in South Africa (aHR 10.66, 95% CI 6.73–16.88), but similar in North America (aHR 0.79, 
95% CI 0.37–1.71). Overall, ICC rates increased with age (>50 years versus 16–30 years, aHR 
1.57, 95% CI 1.03–2.40) and lower CD4 cell counts at ART initiation (per 100 cell/µl decrease, 
aHR 1.25, 95% CI 1.15–1.36). Improving access to early ART initiation and effective cervical 
cancer screening in women living with HIV should be key parts of global efforts to reduce cancer-
related health inequities.
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Introduction
Vast global inequities in the burden of invasive cervical cancer (ICC) exist.1,2 While access 
to effective screening and treatment of pre-cancerous cervical lesions has substantially 
reduced the risk of developing ICC in high-income countries, ICC remains a common cause 
of premature mortality and morbidity in women in low- and middle-income countries.1,2 
ICC disproportionally affects women living with human immunodeficiency virus (HIV), 
who are more likely to have persistent co-infection with high-risk human papillomavirus 
(HPV) types,3 to develop pre-cancerous cervical lesions,4 and to progress to ICC than HIV-
negative women.4 The advent and scale-up of combination antiretroviral therapy (ART) has 
led to a dramatic decline in morbidity and mortality from many HIV-associated diseases,5 
but these decreases have not occurred for ICC.6,7 Indeed, as life expectancy after starting 
ART increases, there is more time for pre-cancerous cervical lesions to develop into ICC, 
but early initiation of ART seems to lower HPV co-infection rates and improve control of 
pre-cancerous cervical lesions.8
Global inequities in ICC incidence rates among women living with HIV have not been 
assessed previously. Our aim was to assess such inequities by comparing ICC incidence 
rates across different geographic regions among women who had initiated ART. 
Additionally, we examined risk factors for developing ICC in these women.
Methods
Databases
We analyzed routinely collected clinical, demographic, laboratory, and treatment data of 
women enrolled in observational HIV cohorts that participate in the International 
epidemiology Databases to Evaluate AIDS (IeDEA) or the Collaboration of Observational 
HIV Epidemiological Research in Europe (COHERE) in EuroCoord. IeDEA has regional 
data centers in the Asia-Pacific, Australia, North America, Latin America and four African 
regions. Cohorts from the following IeDEA regions initially contributed data to this study: 
the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD),9 
the Caribbean, Central and South America network for HIV epidemiology (CCASAnet),10 
IeDEA Southern Africa,11 and IeDEA Asia-Pacific.12 For the IeDEA Southern Africa 
region, we restricted the analysis to two cohorts from South Africa that reduced under-
reporting of cancer cases in the HIV cohorts through record linkages with the National 
Cancer Registry.13 COHERE is a collaboration of observational HIV cohorts across Europe.
14
 It contributed data from 24 cohorts, covering 36 countries. All cohorts obtained ethical 
approval from local ethics committees or institutional review boards, and the Cantonal 
Ethics Committee of Bern (number 028/2015) also granted ethical approval for this study.
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Inclusion criteria and definitions
We restricted the analysis to cohorts that systematically collected cancer data or had 
enhanced their data through record linkages with cancer registries. We included women 
living with HIV who started ART after 1995 at 16 years or older. We excluded women who 
started ART before enrolment into cohort, women without follow-up after ART initiation, 
and women without any CD4 cell count measurements at ART initiation or during follow-
up. We also excluded cohorts with less than 100 eligible women and the Asia-Pacific region 
because of small sample size (post-hoc decision). We analyzed ICC cases diagnosed any 
time after ART initiation as incident cases and excluded women diagnosed with ICC before 
or at ART initiation (prevalent ICC cases) from the analysis. We defined ART as a 
combination of at least three antiretroviral drugs from any class, including protease 
inhibitors (PIs), nucleoside reverse transcriptase inhibitors, and non-nucleoside reverse 
transcriptase inhibitors (NNRTIs). We assumed that women remained on ART and did not 
consider treatment interruptions and terminations. CD4 cell count at ART initiation was 
defined as the cell count closest to ART initiation, during the period within 180 days before 
to seven days after initiation.
Statistical analyses
We calculated raw ICC incidence rates by dividing the number of incident ICC cases by 
person-years (pys) at risk. Time at risk was measured from ART initiation to ICC diagnosis, 
last follow-up visit, death, or database closure, whichever happened first. We used 
proportional hazard flexible parametric survival models15 to estimate regional ICC incidence 
rates and to identify risk factors for developing ICC. We compared ICC rates at 2 years and 
5 years after ART initiation across geographic regions. We used restricted cubic splines with 
4 degrees of freedom and allowed for time-dependent region-effects with 2 degrees of 
freedom to model the baseline hazard. We performed likelihood ratio tests to test 
interactions between risk factors and regions. We assessed the following potential risk 
factors in the analysis: age at ART initiation (16–30, 31–50, >50 years); first-line ART 
regimen (NNRTI-based, PI-based, other); calendar period of ART initiation (1996–1998, 
1999–2003, 2004–2007, 2008–2014); CD4 cell count at ART initiation; and current (time-
updated) CD4 cell count. We treated CD4 cell count at ART initiation and current CD4 cell 
count as continuous variables. Analyses including CD4 cell count at ART initiation were 
restricted to women with available data on this variable. HIV RNA load at ART initiation 
was assessed in descriptive analyses.
We fit a crude model that included only the time-dependent region-effects, resulting in 
region-specific baseline hazards, and no other risk factors. The main adjusted model 
included region, CD4 cell count at ART initiation, age at ART initiation, first-line ART 
regimen, and calendar period of ART initiation. From the main adjusted model, we predicted 
ICC incidence rates for women with a specific set of risk factors, i.e. for women who 
initiated an NNRTI-based regimen between 2008–2014 at age 31–50 years with a CD4 cell 
count of 200 cells/µl. In a sensitivity analysis, the adjusted model included current (time-
updated) CD4 cell count instead of CD4 cell count at ART initiation. In a second sensitivity 
analysis, we excluded ICC cases diagnosed within the first three months after ART initiation 
as prevalent cases and women with less than three months of follow-up. Results are 
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presented as medians with interquartile ranges (IQR), number and percentages of women, 
incidence rates per 100,000 pys and hazard ratios (HRs) with 95% confidence intervals 
(CIs). We used Stata 14 (Stata Corporation, College Station, Texas, USA) and R (R 
Foundation, Vienna, Austria) for our analyses.
Results
Descriptive analyses
The merged dataset included information on 126,063 women living with HIV. We excluded 
44,419 women because they did not receive ART and another 14,413 women for reasons 
detailed in Supplementary Figures S1-S5. We made a post-hoc decision to exclude the Asia-
Pacific region because too few eligible women remained after applying our exclusion 
criteria.
We included data on 64,231 women living with HIV, drawn from 36 cohorts and 45 
countries across Europe, North America, Latin America, and South Africa (Figure 1). 
Overall, median age at ART initiation was 34.9 years (IQR 29.3–41.9), and was higher in 
North America (38.6 years) than in other regions (Table 1). Median CD4 cell count at ART 
initiation was 115 cells/µl (IQR 50–182) in South Africa, 178 cells/µl (IQR 74–281) in Latin 
America, and 241 cells/µl in both North America and Europe (Table 1). In South Africa, less 
than 1% of women started ART before 2004, but 26% of women in Latin America, 40% in 
Europe and 70% in North America initiated ART between 1996 and 2003. Most women in 
South Africa (93%) and Latin America (70%) received an NNRTI-based first-line regimen, 
but the majority of women in the European (55%) and North American (60%) cohorts 
received a PI-based first-line regimen. Median follow-up after ART initiation was around 5 
years in Europe, North, and Latin America, but shorter in South Africa (2.1 years).
Over 320,141 pys of follow-up, 356 incident ICC cases were diagnosed (164 in Europe, 156 
in South Africa, 19 in North America, and 17 in Latin America). In women who developed 
ICC, median time from ART initiation to ICC diagnosis was 1.9 years (IQR 0.7–4.2), and it 
ranged from 1.7 years in South Africa and North America to 2.6 years in Latin America 
(Supplementary Table S1). Median age at ICC diagnosis was 33 years in Latin America, and 
38–40 years in South Africa, North America, and Europe. Median CD4 cell count at ICC 
diagnosis ranged from 275 cells/µl in Latin America to 370 cells/µl in North America.
Comparing ICC risk across regions
The raw ICC incidence rate was highest in South Africa, with 447/100,000 pys (95% CI 
382–523), followed by Latin America (136/100,000 pys; 95% CI 85–219), North America 
(76/100,000 pys; 95% CI 48–119), and Europe (66/100,000 pys; 95% CI 57–77). In Europe, 
North America, and Latin America, there was some evidence for a decrease in crude and 
adjusted ICC incidence rates after more than one year on ART, except in South Africa 
(Figure 2). In crude analyses, ICC rates at 5 years after ART initiation were 11-times higher 
in women living with HIV in South Africa than in their European counterparts (HR 11.06, 
95% CI 7.80–15.68). The much higher ICC rate in South African women was not explained 
by differences in CD4 cell count at ART initiation, age at ART initiation, first-line ART 
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regimen, or calendar period of ART initiation (adjusted HR [aHR] 10.66, 95% CI 6.73–
16.88; see Table 2). In crude (HR 2.32, 95% CI 1.24–4.31) and adjusted analyses (aHR 2.43, 
95% CI 1.27–4.68), ICC rates at 5 years after ART initiation were more than twice as high 
in Latin American as in European women. In North American and European women, ICC 
rates after ART initiation were comparable in crude (HR 0.98, 95% CI 0.48–1.99) and 
adjusted analyses (aHR 0.79, 95% CI 0.37–1.71). The regional comparisons of ICC rates 
were similar at 2 years after ART initiation (Table 2). Also at 2 years after ART initiation, 
ICC rates were much higher in South Africa than in Europe (aHR 6.23, 95% CI 4.29–9.05). 
When we excluded ICC cases diagnosed within the first three months after ART initiation in 
a sensitivity analysis, results did not meaningfully change (Supplementary Table S2).
Risk factors for incident ICC
We did not find evidence of regional variation in the effect of CD4 cell count at ART 
initiation, age at ART initiation, first-line ART regimen, or calendar period of ART initiation 
on the risk of developing ICC (all p-values for interaction ≥ 0.13, see Table 3). Across all 
regions combined, the risk of developing ICC increased among women who initiated ART at 
lower CD4 cell counts (per 100 cell/µl decrease, aHR 1.25, 95% CI 1.15–1.36), and with 
older age at ART initiation (>50 years versus 16–30 years, aHR 1.57, 95% CI 1.03–2.40). 
There was no association between type of first-line ART regimen and the risk of developing 
incident ICC (PI-based versus NNRTI-based, aHR 1.05, 95% CI 0.79–1.41), and we did not 
observe a relevant decline in ICC rates by calendar period of ART initiation. The effects of 
the risk factors assessed in the main adjusted model remained similar when we excluded 
ICC cases diagnosed within the first three months after ART initiation from the analysis 
(Supplementary Table S3).
In a sensitivity analysis, we assessed the effect of current CD4 cell count on the risk of 
developing ICC and found that it varied across regions (p-value for interaction = 0.017). In 
analyses adjusted for age, first-line ART regimen, and calendar period of ART initiation, we 
did not find an association between current CD4 cell count and risk of developing ICC in 
South Africa (per 100 cells/µl decrease, aHR 1.00, 95% CI 0.92–1.10) or North America 
(aHR 1.08, 95% CI 0.90–1.30). However, a decrease of 100 cells/µl in current CD4 cell 
count increased the risk of developing ICC by 18% in European women (aHR 1.18, 95% CI 
1.10–1.27) and 41% in Latin American women (aHR 1.41, 95% CI 1.07–1.86; see 
Supplementary Table S4 and Supplementary Figure S6).
Discussion
Across geographic regions, we found large inequities for cervical cancer incidence in 
women living with HIV. ICC incidence rates were high in women living with HIV in all 
regions studied, but the risk of developing ICC was much higher in women who had initiated 
ART in South Africa or Latin America than in women who had initiated ART in Europe or 
North America. Across all regions combined, the risk of developing ICC increased with 
older age and lower CD4 cell counts at ART initiation.
We believe this is the first study to provide a comparison of ICC incidence rates among 
women living with HIV across several geographic regions. To improve comparability of 
Rohner et al. Page 6
Int J Cancer. Author manuscript; available in PMC 2021 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
results across regions, we applied the same inclusion criteria and statistical methods across 
the whole dataset. With more than 60,000 women and 356 ICC cases included, this is also 
the largest study of ICC incidence in women living with HIV. However, several limitations 
of our study need to be acknowledged. Less than 20 ICC cases each were recorded in Latin 
America and North America. Thus, our comparison of ICC rates between those regions and 
Europe are of limited precision. ICC case identification and validation are likely to vary 
across regions and may have affected observed regional differences in ICC rates. Our results 
for South Africa may not be generalizable to Southern Africa as a region, given that we 
restricted our analyses to two urban cohorts in South Africa, which had been linked with the 
National Cancer Registry to reduce under-reporting of ICC cases. Because we included all 
women who started ART, irrespective of whether they remained in treatment, our results 
may not be representative of women who stayed continuously on ART. HIV RNA 
measurements at ART initiation were missing for one-third of women included in Latin 
America, and almost 80% of women from South Africa. Therefore, we could not use HIV 
RNA load to evaluate treatment response over time. Information on duration of HIV 
infection, HPV co-infection status, cervical cancer screening history, and smoking status was 
generally not available. Thus, we could not explore their effects on the risk of being 
diagnosed with ICC or adjust the regional comparisons for these potential confounders. 
Furthermore, as data on history of hysterectomy were not available, we could not exclude 
women who were no longer at risk of developing ICC. It would also have been interesting to 
assess ICC-related inequities in more depth, but we did not have data on ICC stage at 
diagnosis, for example.
We found that across all regions women living with HIV were at high risk of developing 
ICC after ART initiation. Most previous studies did not restrict their analyses to women who 
had initiated ART, but rather report ICC incidence estimates for women living with HIV 
irrespective of ART use.6,16–18 The raw ICC incidence rates in women living with HIV who 
had initiated ART, ranging from 66/100,000 pys in Europe to 447/100,000 pys in South 
Africa, were substantially higher than the ICC incidence rates reported for women from the 
general population in the included regions (≤30/100,000 pys).2 In our study, ICC rates after 
ART initiation were by far highest in South Africa, followed by Latin America, and they 
were lower in women who had started ART in North America or Europe. These findings 
corroborate the regional ICC incidence rate pattern in the general population,2 but the 
difference between South Africa and other regions is even more pronounced among women 
living with HIV.
The high ICC incidence rates we found in women from South Africa are similar to ICC 
incidence rates in women living with HIV in the United States in the early 1990s.7 In the 
United States, ICC incidence rates in women living with HIV had already dropped in the 
mid-1990s, before ART became available, and this drop has partly been attributed to better 
screening and more effective treatment of pre-cancerous cervical lesions.7 The extent to 
which ART protects women living with HIV from developing ICC is still being explored. 
Although ART reduces the prevalence of high-risk HPV in women living with HIV and 
promotes regression of cervical lesions,8 many women in our analyses, notably in South 
Africa, may have started ART too late, when potentially irreversible pre-cancerous cervical 
lesions were already present. Furthermore, not all women in our study would have achieved 
Rohner et al. Page 7
Int J Cancer. Author manuscript; available in PMC 2021 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
sustained suppression of HIV RNA, and high HIV RNA loads have been associated with an 
increased risk of HPV infection and cervical pre-cancerous lesions.19 Low CD4 cell counts 
have also been associated with a higher risk of HPV infection3 and development of severe 
cervical lesions.20 Accordingly, several studies showed an increased ICC risk in women with 
low nadir,21 baseline,18 or current CD4 cell counts.17 It remains a matter of debate at what 
stage of cervical carcinogenesis the effect of HIV-related immunodeficiency is largest. 
Across all regions combined, we found that the risk of developing ICC increased in women 
who initiated ART at low CD4 cell counts. High current CD4 cell counts had a protective 
effect in Latin America and Europe, but not in North America and South Africa.
Our analyses revealed massive regional differences in ICC rates in women living with HIV. 
Several factors could account for this finding. HPV prevalence in women living with HIV in 
sub-Saharan Africa or Latin America is higher than in North America or Europe,22 and this 
may contribute to the increased ICC burden in South African and Latin American women 
living with HIV. Women in South Africa and Latin America also tended to initiate ART at 
lower CD4 cell counts than women in Europe, and low CD4 cell counts at ART initiation 
increased the risk of developing ICC. Nevertheless, in our analyses large regional differences 
in ICC rates persisted after adjusting for CD4 cell counts. Therefore, inequities in access to 
effective cervical cancer screening and treatment of pre-cancerous cervical lesions are likely 
to be the main driver of regional variation in ICC rates in women living with HIV. 
Substantial global efforts are needed to improve cervical cancer screening and treatment for 
women living with HIV, and to promote national HPV vaccination programmes. 
Unfortunately, most Southern African countries and some regions of Latin America lack the 
resources to treat ICC.23,24
The availability of HPV vaccination and the long natural history from HPV infection 
through cervical intraepithelial neoplasia to invasive cancer make ICC particularly amenable 
to primary and secondary prevention.25 However, it has been estimated that in 2014 less than 
one-third of female adolescents aged 10–20 years in high-income countries and only 1% in 
low-income countries had received the full course of HPV vaccine.26 At present, data on 
HPV vaccination coverage among women living with HIV are lacking.27 Access to 
screening services with early detection and treatment of pre-cancerous cervical lesions 
remains key for ICC prevention in women living with HIV. However, there are extensive 
regional differences in access to effective cervical cancer screening. Less than 10% of 
women living in low-income countries have access to effective cervical cancer screening as 
compared to more than 60% in high-income countries.28 Integrating cervical cancer 
screening services into established HIV care programmes may facilitate screening access for 
women living with HIV and improve sustainability of screening programmes.29 Yet, it 
remains unclear how many women living with HIV actually receive regular screening for 
pre-cancerous cervical lesions. HIV cohorts and integrated cervical cancer screening 
services often do not systematically collect patient-level data on screening and treatment of 
pre-cancerous cervical lesions.30 Rigorous patient-level monitoring of cervical cancer 
screening and treatment programmes is essential to identify coverage gaps and target 
interventions.30
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Conclusion
Our finding that women living with HIV who initiated ART in South Africa or Latin 
America were at much higher risk of developing ICC than women in North America or 
Europe reveals drastic global health inequities. ICC prevention through early ART initiation 
and scale up of effective cervical cancer screening services for women living with HIV, 
alongside the promotion of global access to HPV vaccination should be key parts of 
international efforts to reduce cancer-related health inequities.
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Novelty and impact:
Our study compares invasive cervical cancer (ICC) rates among women living with HIV 
who initiated antiretroviral therapy (ART) across different geographic regions. It shows 
that ICC incidence rates are particularly high in women living with HIV in South Africa 
or Latin America. ICC prevention through early ART initiation, equitable access to 
effective cervical cancer screening, and promotion of human papillomavirus vaccination 
should be key elements of global efforts to reduce cancer-related health inequities.
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Figure 1. 
Map of countries that contributed cohort data; number of included women, by country.
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Figure 2. 
Regional ICC incidence rates with 95% confidence intervals by time since ART initiation, 
predicted from the crude model (red) and the main adjusted model (blue) for women who 
initiated an NNRTI-based regimen between 2008–2014, at age 31–50 years, with a CD4 cell 
count of 200 cells/μl.
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Table 1:
Characteristics of included women at ART initiation.
South Africa Latin America North America Europe
N (%) N (%) N (%) N (%)
All women 13,569 (100%) 2,261 (100%) 4,120 (100%) 44,281 (100%)
Median follow-up time (IQR) [years] 2.1 (0.8–4.1) 5.0 (2.1–8.5) 5.4 (2.3–9.9) 4.8 (2.0–8.5)
Median age at ART initiation (IQR) [years] 35.1 (29.7–41.7) 35.4 (29.3–43.6) 38.6 (32.4–44.8) 34.6 (29.0–41.5)
Age at ART initiation [years]
 16–30 3,584 (26%) 627 (28%) 693 (17%) 12,934 (29%)
 31–50 8,969 (66%) 1,363 (60%) 2,947 (72%) 26,944 (61%)
 >50 1,016 (7%) 271 (12%) 480 (12%) 4,403 (10%)
First-line ART regimen
 NNRTI-based 12,594 (93%) 1,579 (70%) 1,261 (31%) 16,724 (38%)
 PI-based 939 (7%) 623 (28%) 2,476 (60%) 24,325 (55%)
 Other ART 36 (<1%) 59 (3%) 383 (9%) 3,232 (7%)
Year of ART initiation
 1996–1998 0 (0%) 26 (1%) 1,600 (39%) 4,260 (10%)
 1999–2003 51 (<1%) 560 (25%) 1,276 (31%) 13,236 (30%)
 2004–2007 6,791 (50%) 801 (35%) 864 (21%) 12,821 (29%)
 2008–2014 6,727 (50%) 874 (39%) 380 (9%) 13,964 (32%)
Median CD4 cell count at ART initiation (IQR) [cells/µl] 115 (50–182) 178 (74–281) 241 (107–385) 241 (129–363)
CD4 cell count at ART initiation [cells/µl]
 < 50 3,113 (23%) 340 (15%) 577 (14%) 4,676 (11%)
 50–99 2,402 (18%) 274 (12%) 303 (7%) 3,271 (7%)
 100–199 4,733 (35%) 465 (21%) 663 (16%) 7,890 (18%)
 200–349 1,821 (13%) 601 (27%) 1,047 (25%) 13,122 (30%)
 350–499 276 (2%) 154 (7%) 587 (14%) 6,146 (14%)
 500–699 139 (1%) 74 (3%) 349 (8%) 3,069 (7%)
 ≥ 700 66 (<1%) 30 (1%) 170 (4%) 1,638 (4%)
 Missing 1,019 (8%) 323 (14%) 424 (10%) 4,469 (10%)
Median HIV RNA at ART initiation (IQR) [log10 copies/ml] 4.4 (2.6–5.2) 4.8 (4.0–5.3) 4.3 (3.4–5.0) 4.5 (3.7–5.1)
HIV RNA at ART initiation [log10 copies/ml]
 < 2.7 788 (6%) 91 (4%) 608 (15%) 4,704 (11%)
 2.7–3.9 404 (3%) 260 (11%) 806 (20%) 7,319 (17%)
 4.0–4.9 870 (6%) 585 (26%) 1,218 (30%) 14,051 (32%)
 ≥ 5.0 984 (7%) 568 (25%) 946 (23%) 11,764 (27%)
 Missing 10,523 (78%) 757 (33%) 542 (13%) 6,443 (15%)
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ART, antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile range; NNRTI, non-nucleoside reverse-transcriptase inhibitor; 
PI, protease-inhibitor; RNA, ribonucleic acid.
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Table 2:
Comparison of ICC rates between different regions and Europe:
Crude and adjusted HRs for ICC at 2 years and 5 years after ART initiation in women living with HIV.
At 2 years At 5 years
Crude HR (95% CI) Adjusted HR* (95% CI) Crude HR (95% CI) Adjusted HR* (95% CI)
Region
 Europe 1.00 1.00 1.00 1.00
 North America 1.81 (0.94 – 3.48) 1.51 (0.73 – 3.12) 0.98 (0.48 – 1.99) 0.79 (0.37 – 1.71)
 Latin America 1.93 (1.09 – 3.42) 1.83 (0.99 – 3.37) 2.32 (1.24 – 4.31) 2.43 (1.27 – 4.68)
 South Africa 6.84 (5.20 – 9.00) 6.23 (4.29 – 9.05) 11.06 (7.80 – 15.68) 10.66 (6.73 – 16.88)
*Adjusted for CD4 cell count at ART initiation, age at ART initiation, first-line ART regimen, and calendar period of ART initiation.
ART, antiretroviral therapy; CI, confidence interval; HR, hazard ratio; ICC, invasive cervical cancer.
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Table 3:
Adjusted hazard ratios for the effect of different factors on the risk of developing incident ICC in women who 
have initiated ART.
Hazard ratio* (95% CI) p-value for interaction**
CD4 cell count at ART initiation 0.76
 per 100 cells/µl decrease 1.25 (1.15 – 1.36)
Age at ART initiation [years] 0.34
 16–30 1.00
 31–50 1.38 (1.05 – 1.81)
 >50 1.57 (1.03 – 2.40)
First-line ART regimen 0.21
 NNRTI-based 1.00
 PI-based 1.05 (0.79 – 1.41)
 Other ART 0.57 (0.27 – 1.18)
Year of ART initiation 0.13
 1996–1998 1.49 (0.92 – 2.42)
 1999–2003 1.19 (0.80 – 1.77)
 2004–2007 0.83 (0.61 – 1.14)
 2008–2014 1.00
*Adjusted for region, CD4 cell count at ART initiation, age at ART initiation, calendar year of ART initiation, and first-line ART regimen.
**
Derived from likelihood ratio test comparing the adjusted model with and without the interaction of a specific variable with region.
ART, antiretroviral therapy; CI, confidence interval; ICC, invasive cervical cancer; NNRTI, non-nucleoside reverse-transcriptase inhibitor; PI, 
protease-inhibitor
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